問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

Division of Endocrinology

更新時間:2023-09-19

夏建勳
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

28Cases

2025-07-01 - 2028-05-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)
  • Condition/Disease

    Atherosclerotic Cardiovascular Disease (ASCVD)

  • Test Drug

    Prefilled Injectable

Participate Sites
5Sites

Recruiting5Sites

2009-07-01 - 2010-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-03-31 - 2027-06-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Terminated15Sites

2021-01-01 - 2025-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2015-05-01 - 2021-05-01

Phase IV

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-10-02 - 2030-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-07-01 - 2026-01-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-12-10 - 2025-10-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2024-05-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2012-12-01 - 2019-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 2 3